acamprosate vs olanzapine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and olanzapine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Zyprexa
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Olanzapine is a medicine used to treat certain mental disorders. It helps to balance chemicals in the brain to improve mood and behavior.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Olanzapine is used to treat schizophrenia in adults and teens (13-17). It also treats manic or mixed episodes of bipolar I disorder in adults and teens (13-17). In adults, it can be used with other medicines to treat bipolar depression.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Olanzapine is an atypical antipsychotic. It works by affecting the levels of certain chemicals in your brain. These chemicals include dopamine and serotonin, which can help improve mood, thinking, and behavior.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Dizziness
- • Weight gain
- • Increased appetite
- • Dry mouth
- • Constipation
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Weight Increased 6,722
- Diabetes Mellitus 5,388
- Drug Interaction 4,048
- Toxicity To Various Agents 3,966
- Somnolence 3,839
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Olanzapine can increase the risk of death in older adults with dementia-related psychosis. Olanzapine is not approved to treat this condition. When using olanzapine with fluoxetine, read the Symbyax label for more warnings.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
If you take olanzapine during the third trimester of pregnancy, your baby may have withdrawal symptoms after birth. There is a pregnancy registry to monitor outcomes in women who take atypical antipsychotics during pregnancy. Talk to your doctor.
Also Compare, Nearby Drugs
Compare olanzapine with
How to Read This acamprosate vs olanzapine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while olanzapine sits within the Atypical Antipsychotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while olanzapine has 23,963. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or olanzapine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.